Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | CASP6 | P55212 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | PDE10A | Q9Y233 | 5/20 | 0.45 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.44 |
| ▸ | PDE2A | O00408 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31428884 | 1.00 | CYP1A2 (0.57) | CYP1A2KDM4ELMNAPOLBCASP6 | |
| SCHEMBL21618429 | 0.84 | CYP1A2 (0.61) | CYP1A2KDM4ELMNAPOLBCASP6 | |
| SCHEMBL10234988 | 0.82 | CYP1A2 (0.59) | CYP1A2KDM4ELMNAPOLBCASP6 | |
| SCHEMBL30647549 | 0.81 | CYP1A2 (0.57) | CYP1A2KDM4ELMNAPOLBCASP6 | |
| SCHEMBL1206321 | 0.81 | CYP1A2 (0.57) | CYP1A2KDM4ELMNAPOLBCASP6 | |
| SCHEMBL29518266 | 0.81 | CYP1A2 (0.57) | CYP1A2KDM4ELMNAPOLBCASP6 | |
| SCHEMBL554745 | 0.81 | CYP1A2 (0.57) | CYP1A2KDM4ELMNAPOLBCASP6 | |
| SCHEMBL15287165 | 0.81 | KDM4E (0.58) | CYP1A2KDM4ELMNAPOLBCASP6 | |
| SCHEMBL28136977 | 0.81 | CYP1A2 (0.57) | CYP1A2KDM4ELMNAPOLBCASP6 | |
| SCHEMBL21064680 | 0.79 | CYP1A2 (0.55) | CYP1A2KDM4ELMNAPOLBCASP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024059186-A1 | N-((ISOQUINOLIN-6-YL)METHYL)-1H-PYRAZOLE-4-CARBOXAMID DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS FOR THE TREATMENT OF HEREDITARY ANGIOEDEMA | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-03-21 | — | — | WO | disclosed |
| WO-2022068772-A1 | BENZIMIDAZOLE DERIVATIVE, AND PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | 深圳信立泰药业股份有限公司 | 2022-04-07 | — | — | WO | disclosed |
| WO-2022068772-A1 | BENZIMIDAZOLE DERIVATIVE, AND PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | 深圳信立泰药业股份有限公司 | 2022-04-07 | — | — | WO | disclosed |
| CN-109776507-B | Preparation method of 2-methyl-4- (tetrahydrofuran-2-yl) quinoline derivative | 济南大学 | 2021-11-23 | — | — | CN | disclosed |
| US-9834513-B2 | Benzylamine derivatives | Kalvista Pharmceuticals Limited (GB) | 2017-12-05 | — | — | US | disclosed |
| US-9834513-B2 | Benzylamine derivatives | Kalvista Pharmceuticals Limited (GB) | 2017-12-05 | — | — | US | disclosed |
| US-20170253561-A1 | Benzylamine Derivatives | KALVISTA PHARMACEUTICALS LTD (GB) | 2017-09-07 | — | — | US | disclosed |
| US-20170253561-A1 | Benzylamine Derivatives | KALVISTA PHARMACEUTICALS LTD (GB) | 2017-09-07 | — | — | US | disclosed |
| US-9670157-B2 | Benzylamine derivatives | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2017-06-06 | — | — | US | disclosed |
| US-9670157-B2 | Benzylamine derivatives | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2017-06-06 | — | — | US | disclosed |
| US-20120035168-A1 | N-((6-AMINO-PYRIDIN-3-YL)METHYL)-HETEROARYL-CARBOXAMIDES | NOVARTIS AG (CH) | 2012-02-09 | — | — | US | disclosed |
| US-20120035168-A1 | N-((6-AMINO-PYRIDIN-3-YL)METHYL)-HETEROARYL-CARBOXAMIDES | NOVARTIS AG (CH) | 2012-02-09 | — | — | US | disclosed |
| US-20120035168-A1 | N-((6-AMINO-PYRIDIN-3-YL)METHYL)-HETEROARYL-CARBOXAMIDES | NOVARTIS AG (CH) | 2012-02-09 | — | — | US | disclosed |
| WO-2012017020-A1 | N-((6-AMINO-PYRIDIN-3-YL)METHYL)-HETEROARYL-CARBOXAMIDES AS INHIBITORS OF PLASMA KALLIKREIN | NOVARTIS AG (CH) | 2012-02-09 | — | — | WO | disclosed |
| US-20110275643-A1 | AROYLQUINOLINE COMPOUNDS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2011-11-10 | — | — | US | disclosed |
| US-20100227846-A1 | SUBSTITUTED PYRAZOLE DERIVATIVE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-09 | — | — | US | disclosed |
| EP-2194045-A1 | SUBSTITUTED PYRAZOLE DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2010-06-09 | — | — | EP | disclosed |
| US-20090270359-A1 | SUBSTITUTED PYRAZOLE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-29 | — | — | US | disclosed |
| US-4962203-A | ANTIASTHMATIC, ANTIALLERGENIC, ANTIINFLAMMATORY AND CYTOPROTECTIVE AGENTS | MERCK FROST CANADA, INC. (CA) | 1990-10-09 | — | — | US | disclosed |
| EP-0206751-A2 | 2-Substituted quinolines, their preparation and use | MERCK FROSST CANADA INC. (CA) | 1986-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227846-A1 | SUBSTITUTED PYRAZOLE DERIVATIVE | AR, NR5A1, NR3C2 | CYP1A2 164/4885KDM4E 1414/4885LMNA 4608/4885 |
| US-20090270359-A1 | SUBSTITUTED PYRAZOLE DERIVATIVES | AR, NR5A1, NR3C2 | CYP1A2 160/4885KDM4E 1440/4885LMNA 4607/4885 |
| US-20110275643-A1 | AROYLQUINOLINE COMPOUNDS | TUBA1C, TUBB1, TUBB3 | CYP1A2 622/4885KDM4E 3377/4885LMNA 3300/4885 |
| US-20120035168-A1 | N-((6-AMINO-PYRIDIN-3-YL)METHYL)-HETEROARYL-CARBOXAMIDES | TPMT, REN, PNMT | CYP1A2 117/4885KDM4E 927/4885LMNA 1188/4885 |
| US-20170253561-A1 | Benzylamine Derivatives | BDKRB1, BDKRB2, KLKB1 | CYP1A2 1641/4885KDM4E 577/4885LMNA 619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.